Stocktoria
VIEMED HEALTHCARE, INC. VMD
VIEMED HEALTHCARE, INC. (VMD) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $270.3M at a 5.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.19 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.037 |
| Retained earnings / assets | 0.517 |
| EBIT / assets | 0.115 |
| Equity / liabilities | 2.58 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VMD | VIEMED HEALTHCARE, INC. | 5/9 | 5.41 | 26.5 | +20.5% |
| CCEL | CRYO CELL INTERNATIONAL INC | 5/9 | -3.07 | — | -1.3% |
| NIVF | NewGenIvf Group Ltd | 3/9 | 3.84 | 0.6 | — |
| MGRX | MANGOCEUTICALS, INC. | 2/9 | 2.42 | — | — |
| BRTX | BioRestorative Therapies, Inc. | 3/9 | — | — | — |
| SHC | Sotera Health Co | 6/9 | — | 63.6 | +5.7% |
| PGNY | Progyny, Inc. | 5/9 | 7.14 | 38.2 | +10.4% |
About VIEMED HEALTHCARE, INC.
Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. It also sells and rents HME devices, such as non-invasive and invasive ventilators, positive airway pressure (PAP) machines, durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment. In addition, the company provides neuromuscular care and oxygen therapy services; and sleep apnea management which provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, it offers in-home sleep apnea testing services; and breast pumps and related lactation equipment and supplies, including fulfillment and support services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.
FAQ
Is VMD financially healthy?
VIEMED HEALTHCARE, INC.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does VMD pay a dividend?
No, VIEMED HEALTHCARE, INC. does not currently pay a dividend.
How profitable is VMD?
In FY2025, VIEMED HEALTHCARE, INC. had a net margin of 5.5% and a return on equity of 10.4%.
Is VMD overvalued or undervalued?
VIEMED HEALTHCARE, INC. trades at about 25.0× trailing earnings — near its 10-year norm (10-year range 10.8×–53.1×, median 25.0×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for VMD?
The average Wall-Street price target for VIEMED HEALTHCARE, INC. is $11.00, about 18.8% above the recent price, from 1 analysts.
Is VMD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on VIEMED HEALTHCARE, INC.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 26.5×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.